Pharmacokinetic and safety study of weekly irinotecan and oral capecitabine in patients with advanced solid cancers

Background: Capecitabine and irinotecan have demonstrated in vitro synergistic anti-cancer activity, and both are substrates for carboxyl esterases (CES). We conducted a study to identify a safe dose and potential drug-drug interactions of this combination.